LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 257

Search options

  1. Article ; Online: Towards Intermittent Preventive Therapy in Pregnancy with Dihydroartemisinin-Piperaquine?

    Ter Kuile, Feiko O

    Clinical pharmacology and therapeutics

    2021  Volume 110, Issue 6, Page(s) 1432–1434

    MeSH term(s) Artemisinins ; Female ; Humans ; Pregnancy ; Quinolines/adverse effects
    Chemical Substances Artemisinins ; Quinolines ; artenimol (6A9O50735X) ; piperaquine (A0HV2Q956Y)
    Language English
    Publishing date 2021-08-26
    Publishing country United States
    Document type Journal Article ; Comment
    ZDB-ID 123793-7
    ISSN 1532-6535 ; 0009-9236
    ISSN (online) 1532-6535
    ISSN 0009-9236
    DOI 10.1002/cpt.2394
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Global estimates of the number of pregnancies at risk of malaria from 2007 to 2020: a demographic study.

    Reddy, Valentina / Weiss, Daniel J / Rozier, Jennifer / Ter Kuile, Feiko O / Dellicour, Stephanie

    The Lancet. Global health

    2022  Volume 11, Issue 1, Page(s) e40–e47

    Abstract: Background: The most recent global estimates of the number of pregnancies at risk of Plasmodium falciparum and Plasmodium vivax malaria infection are from 2007. To inform global malaria prevention and control efforts, we aimed to estimate the global ... ...

    Abstract Background: The most recent global estimates of the number of pregnancies at risk of Plasmodium falciparum and Plasmodium vivax malaria infection are from 2007. To inform global malaria prevention and control efforts, we aimed to estimate the global distribution of pregnancies at risk of malaria infection from 2007 to 2020.
    Methods: We used estimates from the Malaria Atlas Project on the total population living in areas of P falciparum and P vivax transmission, combined with country-specific demographic data on women of reproductive age, fertility rates, induced abortions, and stillbirths, to derive the annual number of pregnancies overall, by parasite species, and by endemicity strata from 2007 to 2020. The definition of endemicity strata was based on the parasite point prevalence in individuals aged 2-10 years for P falciparum and 1-99 years for P vivax. We also did a sensitivity analysis in which we considered most of sub-Saharan Africa endemic for P vivax.
    Findings: In 2020, 121·9 million pregnancies occurred in malaria transmission areas, resulting in an estimated 70·9 million (58·1%) livebirths. The total number of pregnancies at risk of malaria was 52·9 million in the WHO South-East Asia (SEARO) region, 5·1 million in the Western Pacific (WPRO) region, 46·1 million in the Africa (AFRO) region, 11·1 million in the Eastern Mediterranean (EMRO) region, and 6·7 million in the Americas (AMRO) region. Between 2007 and 2020, pregnancies in areas of P falciparum transmission declined by 11·4% globally, despite an overall 7·0% increase in pregnancies, representing a decrease of 100·0% in the WHO Europe (EURO) region, 52·6% in WPRO, 51·5% in AMRO, 23·9% in EMRO, and 17·2% in SEARO, and a 25·4% increase in AFRO. Pregnancies in P vivax transmission areas fell by 42·8%, representing a decrease of 100·0% in EURO, 89·8% in WPRO, 48·4% in AMRO, 32·4% in EMRO, and 10·0% in SEARO, and a 25·8% increase in AFRO. Our sensitivity analysis suggests that the number of pregnancies at risk of P vivax infection could be seven-fold higher for AFRO if the whole of sub-Saharan Africa was considered endemic for P vivax.
    Interpretation: Between 2007 and 2020, substantial declines in the number of pregnancies at risk of malaria were seen globally. However, in AFRO, 25·4% more pregnancies were at risk of P falciparum or P vivax malaria than in 2007. This increase in the number at risk in AFRO comes despite the decline in malaria rates due to the rapidly rising population and the corresponding number of pregnancies in endemic areas. These estimates should guide priority setting for resource allocation to control malaria in pregnancy.
    Funding: Bill & Melinda Gates Foundation and Telethon Trust.
    MeSH term(s) Pregnancy ; Female ; Humans ; Malaria/epidemiology ; Malaria, Vivax/epidemiology ; Malaria, Falciparum/epidemiology ; Plasmodium falciparum ; Africa South of the Sahara ; Prevalence
    Language English
    Publishing date 2022-12-15
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2723488-5
    ISSN 2214-109X ; 2214-109X
    ISSN (online) 2214-109X
    ISSN 2214-109X
    DOI 10.1016/S2214-109X(22)00431-4
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Perceptions and drivers of healthcare provider and drug dispenser practices for the treatment of malaria in pregnancy in the context of multiple first-line therapies in western Kenya: a qualitative study.

    Osoro, Caroline B / Dellicour, Stephanie / Ochodo, Eleanor / Young, Taryn / Ter Kuile, Feiko O / Gutman, Julie R / Hill, Jenny

    Malaria journal

    2023  Volume 22, Issue 1, Page(s) 274

    Abstract: Background: Emergence of Plasmodium falciparum resistance to artemether-lumefantrine in Africa prompted the pilot introduction of multiple first-line therapies (MFT) against malaria in Kenya, potentially exposing women-of-childbearing-age (WOCBAs) to ... ...

    Abstract Background: Emergence of Plasmodium falciparum resistance to artemether-lumefantrine in Africa prompted the pilot introduction of multiple first-line therapies (MFT) against malaria in Kenya, potentially exposing women-of-childbearing-age (WOCBAs) to anti-malarials with unknown safety profiles in the first trimester. This qualitative study explored knowledge and perceptions among healthcare providers providing malaria treatment to WOCBAs and pregnant women.
    Methods: In-depth interviews were conducted with purposively selected public and private health facility (HF) and drug outlet (DO) providers within and outside the pilot-MFT area. County health managers were interviewed about their knowledge of the national treatment guidelines. Transcripts were coded by content analysis using the World Health Organization health system building blocks (leadership/governance, financing, health workforce, health information systems, access to medicines, and service delivery).
    Results: Thirty providers (HF:21, DO:9) and three health managers were interviewed. Eighteen providers were from HFs in the pilot-MFT area; the remaining three and all nine DOs were outside the pilot-MFT area. The analysis revealed that providers had not been trained in malaria case management in the previous twelve months. DO providers were unfamiliar with national treatment guidelines in pregnancy and reported having no pregnancy tests. Health managers were unable to supervise DOs due to resource limitations. Providers from HFs and DOs noted poor sensitivity of malaria rapid diagnostic tests (RDTs) and hesitancy among patients who associated malaria-RDTs with HIV testing. Almost all providers reported anti-malarial stock-outs, with quinine most affected. Patient preference was a major factor in prescribing anti-malarials. Providers in HFs and DOs reported preferentially using artemether-lumefantrine in the first trimester due to the side effects and unavailability of quinine.
    Conclusion: Knowledge of malaria case management in drug outlets and health facilities remains poor. Improved regulation of DO providers is warranted. Optimizing treatment of malaria in pregnancy requires training, availability of malaria commodities, and pregnancy tests.
    MeSH term(s) Pregnancy ; Humans ; Female ; Antimalarials/therapeutic use ; Kenya ; Pharmaceutical Preparations ; Quinine ; Artemether ; Artemether, Lumefantrine Drug Combination/therapeutic use ; Malaria/drug therapy ; Health Personnel
    Chemical Substances Antimalarials ; Pharmaceutical Preparations ; Quinine (A7V27PHC7A) ; Artemether (C7D6T3H22J) ; Artemether, Lumefantrine Drug Combination
    Language English
    Publishing date 2023-09-14
    Publishing country England
    Document type Journal Article
    ZDB-ID 2091229-8
    ISSN 1475-2875 ; 1475-2875
    ISSN (online) 1475-2875
    ISSN 1475-2875
    DOI 10.1186/s12936-023-04698-w
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article: Policy uptake and implementation of the RTS,S/AS01 malaria vaccine in sub-Saharan African countries: status 2 years following the WHO recommendation.

    Osoro, Caroline Bonareri / Ochodo, Eleanor / Kwambai, Titus K / Otieno, Jenifer Akoth / Were, Lisa / Sagam, Caleb Kimutai / Owino, Eddy Johnson / Kariuki, Simon / Ter Kuile, Feiko O / Hill, Jenny

    BMJ global health

    2024  Volume 9, Issue 4

    Abstract: In October 2021, the WHO recommended the world's first malaria vaccine-RTS,S/AS01-to prevent malaria in children living in areas with moderate-to-high transmission in sub-Saharan Africa (SSA). A second malaria vaccine, R21/Matrix-M, was recommended for ... ...

    Abstract In October 2021, the WHO recommended the world's first malaria vaccine-RTS,S/AS01-to prevent malaria in children living in areas with moderate-to-high transmission in sub-Saharan Africa (SSA). A second malaria vaccine, R21/Matrix-M, was recommended for use in October 2023 and added to the WHO list of prequalified vaccines in December 2023. This study analysis assessed the country status of implementation and delivery strategies for RTS,S/AS01 by searching websites for national malaria policies, guidelines and related documents. Direct contact with individuals working in malaria programmes was made to obtain documents not publicly available. 10 countries had documents with information relating to malaria vaccine implementation, 7 referencing RTS,S/AS01 and 3 (Burkina Faso, Kenya and Nigeria) referencing RTS,S/AS01 and R21/Matrix-M. Five other countries reported plans for malaria vaccine roll-out without specifying which vaccine. Ghana, Kenya and Malawi, which piloted RTS,S/AS01, have now integrated the vaccine into routine immunisation services. Cameroon and Burkina Faso are the first countries outside the pilot countries to incorporate the vaccine into national immunisation services. Uganda plans a phased RTS,S/AS01 introduction, while Guinea plans to first pilot RTS,S/AS01 in five districts. The RTS,S/AS01 schedule varied by country, with the first dose administered at 5 or 6 months in all countries but the fourth dose at either 18, 22 or 24 months. SSA countries have shown widespread interest in rolling out the malaria vaccine, the Global Alliance for Vaccines and Immunization having approved financial support for 20 of 30 countries which applied as of March 2024. Limited availability of RTS,S/AS01 means that some approved countries will not receive the required doses. Vaccine availability and equity must be addressed even as R21/Matrix-M becomes available.
    MeSH term(s) Humans ; Malaria Vaccines/administration & dosage ; Africa South of the Sahara ; World Health Organization ; Malaria/prevention & control ; Immunization Programs ; Health Policy
    Chemical Substances Malaria Vaccines
    Language English
    Publishing date 2024-04-30
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Review
    ISSN 2059-7908
    ISSN 2059-7908
    DOI 10.1136/bmjgh-2023-014719
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Back to chloroquine for malaria prophylaxis in pregnancy?

    Chico, R Matthew / Ter Kuile, Feiko O

    The Lancet. Infectious diseases

    2018  Volume 18, Issue 10, Page(s) 1051–1052

    MeSH term(s) Antimalarials ; Chemoprevention ; Chloroquine ; Female ; Humans ; Malaria/prevention & control ; Malawi ; Pregnancy
    Chemical Substances Antimalarials ; Chloroquine (886U3H6UFF)
    Language English
    Publishing date 2018-09-05
    Publishing country United States
    Document type Journal Article ; Comment
    ZDB-ID 2061641-7
    ISSN 1474-4457 ; 1473-3099
    ISSN (online) 1474-4457
    ISSN 1473-3099
    DOI 10.1016/S1473-3099(18)30427-4
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: PRObiotics and SYNbiotics to improve gut health and growth in infants in western Kenya (PROSYNK Trial): study protocol for a 4-arm, open-label, randomised, controlled trial.

    Otiti, Mary Iwaret / Kariuki, Simon / Wang, Duolao / Hall, Lindsay J / Ter Kuile, Feiko O / Allen, Stephen

    Trials

    2022  Volume 23, Issue 1, Page(s) 284

    Abstract: Background: Malnutrition amongst under-fives remains common in resource-poor countries and is resistant to current interventions. New opportunities have emerged to target "environmental enteric dysfunction" (EED) that refers to the abnormal gut ... ...

    Abstract Background: Malnutrition amongst under-fives remains common in resource-poor countries and is resistant to current interventions. New opportunities have emerged to target "environmental enteric dysfunction" (EED) that refers to the abnormal gut structure and function that results from colonisation of the gut with pathogenic microbes and compromises nutrition and growth in early life. Although the gut microbiome may provide a defence against ingested gut pathogens through colonisation resistance, its development is adversely affected by multiple environmental factors. Dietary supplements of pro- or synbiotics may build the resilience of the gut microbiome against these environmental factors and boost colonisation resistance. We aim to assess whether dietary supplementation of newborns in rural Kenya with pro/synbiotics prevents or ameliorates EED and improves growth.
    Methods: Six hundred newborns less than 4 days old will be recruited from Homa Bay County Teaching and Referral Hospital, western Kenya. Newborns will be randomly allocated, stratified by HIV exposure, in a 1:1:1:1 ratio to one of 4 study arms to receive either of two synbiotics, a probiotic or no supplement. Supplements will be given daily for 10 days and then weekly until 6 months of age. Participants will be followed until the age of 2 years. The primary outcome is systemic inflammation at 6 months assessed by plasma alpha-1-acid glycoprotein. Secondary outcomes include biomarkers of gut health and growth, anthropometric indices, morbidity and mortality.
    Discussion: As dietary supplements with pro- or synbiotics may improve gut health and can be administered in early life, our findings may inform the package of interventions to prevent malnutrition and improve growth in Africa and similar low-resource settings.
    Trial registration: Pan African Clinical Trials Registry, Trial number: PACTR202003893276712. Date: 02/03/2020 https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=9798.
    MeSH term(s) Child, Preschool ; Gastrointestinal Microbiome ; Humans ; Infant ; Infant, Newborn ; Kenya ; Malnutrition ; Probiotics/adverse effects ; Randomized Controlled Trials as Topic ; Synbiotics
    Language English
    Publishing date 2022-04-11
    Publishing country England
    Document type Clinical Trial Protocol ; Journal Article
    ZDB-ID 2040523-6
    ISSN 1745-6215 ; 1468-6694 ; 1745-6215
    ISSN (online) 1745-6215
    ISSN 1468-6694 ; 1745-6215
    DOI 10.1186/s13063-022-06211-1
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Chemoprevention for malaria with monthly intermittent preventive treatment with dihydroartemisinin-piperaquine in pregnant women living with HIV on daily co-trimoxazole in Kenya and Malawi: a randomised, double-blind, placebo-controlled trial.

    Barsosio, Hellen C / Madanitsa, Mwayiwawo / Ondieki, Everlyne D / Dodd, James / Onyango, Eric D / Otieno, Kephas / Wang, Duolao / Hill, Jenny / Mwapasa, Victor / Phiri, Kamija S / Maleta, Kenneth / Taegtmeyer, Miriam / Kariuki, Simon / Schmiegelow, Christentze / Gutman, Julie R / Ter Kuile, Feiko O

    Lancet (London, England)

    2024  Volume 403, Issue 10424, Page(s) 365–378

    Abstract: Background: The efficacy of daily co-trimoxazole, an antifolate used for malaria chemoprevention in pregnant women living with HIV, is threatened by cross-resistance of Plasmodium falciparum to the antifolate sulfadoxine-pyrimethamine. We assessed ... ...

    Abstract Background: The efficacy of daily co-trimoxazole, an antifolate used for malaria chemoprevention in pregnant women living with HIV, is threatened by cross-resistance of Plasmodium falciparum to the antifolate sulfadoxine-pyrimethamine. We assessed whether addition of monthly dihydroartemisinin-piperaquine to daily co-trimoxazole is more effective at preventing malaria infection than monthly placebo plus daily co-trimoxazole in pregnant women living with HIV.
    Methods: We did an individually randomised, two-arm, placebo-controlled trial in areas with high-grade sulfadoxine-pyrimethamine resistance in Kenya and Malawi. Pregnant women living with HIV on dolutegravir-based combination antiretroviral therapy (cART) who had singleton pregnancies between 16 weeks' and 28 weeks' gestation were randomly assigned (1:1) by computer-generated block randomisation, stratified by site and HIV status (known positive vs newly diagnosed), to daily co-trimoxazole plus monthly dihydroartemisinin-piperaquine (three tablets of 40 mg dihydroartemisinin and 320 mg piperaquine given daily for 3 days) or daily co-trimoxazole plus monthly placebo. Daily co-trimoxazole consisted of one tablet of 160 mg sulfamethoxazole and 800 mg trimethoprim. The primary endpoint was the incidence of Plasmodium infection detected in the peripheral (maternal) or placental (maternal) blood or tissue by PCR, microscopy, rapid diagnostic test, or placental histology (active infection) from 2 weeks after the first dose of dihydroartemisinin-piperaquine or placebo to delivery. Log-binomial regression was used for binary outcomes, and Poisson regression for count outcomes. The primary analysis was by modified intention to treat, consisting of all randomised eligible participants with primary endpoint data. The safety analysis included all women who received at least one dose of study drug. All investigators, laboratory staff, data analysts, and participants were masked to treatment assignment. This trial is registered with ClinicalTrials.gov, NCT04158713.
    Findings: From Nov 11, 2019, to Aug 3, 2021, 904 women were enrolled and randomly assigned to co-trimoxazole plus dihydroartemisinin-piperaquine (n=448) or co-trimoxazole plus placebo (n=456), of whom 895 (99%) contributed to the primary analysis (co-trimoxazole plus dihydroartemisinin-piperaquine, n=443; co-trimoxazole plus placebo, n=452). The cumulative risk of any malaria infection during pregnancy or delivery was lower in the co-trimoxazole plus dihydroartemisinin-piperaquine group than in the co-trimoxazole plus placebo group (31 [7%] of 443 women vs 70 [15%] of 452 women, risk ratio 0·45, 95% CI 0·30-0·67; p=0·0001). The incidence of any malaria infection during pregnancy or delivery was 25·4 per 100 person-years in the co-trimoxazole plus dihydroartemisinin-piperaquine group versus 77·3 per 100 person-years in the co-trimoxazole plus placebo group (incidence rate ratio 0·32, 95% CI 0·22-0·47, p<0·0001). The number needed to treat to avert one malaria infection per pregnancy was 7 (95% CI 5-10). The incidence of serious adverse events was similar between groups in mothers (17·7 per 100 person-years in the co-trimoxazole plus dihydroartemisinin-piperaquine group [23 events] vs 17·8 per 100 person-years in the co-trimoxazole group [25 events]) and infants (45·4 per 100 person-years [23 events] vs 40·2 per 100 person-years [21 events]). Nausea within the first 4 days after the start of treatment was reported by 29 (7%) of 446 women in the co-trimoxazole plus dihydroartemisinin-piperaquine group versus 12 (3%) of 445 women in the co-trimoxazole plus placebo group. The risk of adverse pregnancy outcomes did not differ between groups.
    Interpretation: Addition of monthly intermittent preventive treatment with dihydroartemisinin-piperaquine to the standard of care with daily unsupervised co-trimoxazole in areas of high antifolate resistance substantially improves malaria chemoprevention in pregnant women living with HIV on dolutegravir-based cART and should be considered for policy.
    Funding: European and Developing Countries Clinical Trials Partnership 2; UK Joint Global Health Trials Scheme (UK Foreign, Commonwealth and Development Office; Medical Research Council; National Institute for Health Research; Wellcome); and Swedish International Development Cooperation Agency.
    MeSH term(s) Female ; Humans ; Infant ; Pregnancy ; Antimalarials/adverse effects ; Artemisinins ; Chemoprevention ; Folic Acid Antagonists/therapeutic use ; HIV Infections/epidemiology ; HIV Infections/prevention & control ; HIV Infections/drug therapy ; Kenya/epidemiology ; Malaria/epidemiology ; Malaria/prevention & control ; Malawi/epidemiology ; Piperazines ; Placenta ; Pregnancy Outcome ; Pregnant Women ; Quinolines ; Trimethoprim, Sulfamethoxazole Drug Combination/therapeutic use ; Double-Blind Method
    Chemical Substances Antimalarials ; Artemisinins ; artenimol (6A9O50735X) ; Folic Acid Antagonists ; piperaquine (A0HV2Q956Y) ; Piperazines ; Quinolines ; Trimethoprim, Sulfamethoxazole Drug Combination (8064-90-2)
    Language English
    Publishing date 2024-01-12
    Publishing country England
    Document type Randomized Controlled Trial ; Journal Article
    ZDB-ID 3306-6
    ISSN 1474-547X ; 0023-7507 ; 0140-6736
    ISSN (online) 1474-547X
    ISSN 0023-7507 ; 0140-6736
    DOI 10.1016/S0140-6736(23)02631-4
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Malaria in pregnancy (MiP) studies assessing the clinical performance of highly sensitive rapid diagnostic tests (HS-RDT) for Plasmodium falciparum detection.

    Ding, Xavier C / Incardona, Sandra / Serra-Casas, Elisa / Charnaud, Sarah C / Slater, Hannah C / Domingo, Gonzalo J / Adams, Emily R / Ter Kuile, Feiko O / Samuels, Aaron M / Kariuki, Simon / Dittrich, Sabine

    Malaria journal

    2023  Volume 22, Issue 1, Page(s) 60

    Abstract: Background: Rapid diagnostic tests (RDTs) are effective tools to diagnose and inform the treatment of malaria in adults and children. The recent development of a highly sensitive rapid diagnostic test (HS-RDT) for Plasmodium falciparum has prompted ... ...

    Abstract Background: Rapid diagnostic tests (RDTs) are effective tools to diagnose and inform the treatment of malaria in adults and children. The recent development of a highly sensitive rapid diagnostic test (HS-RDT) for Plasmodium falciparum has prompted questions over whether it could improve the diagnosis of malaria in pregnancy and pregnancy outcomes in malaria endemic areas.
    Methods: This landscape review collates studies addressing the clinical performance of the HS-RDT. Thirteen studies were identified comparing the HS-RDT and conventional RDT (co-RDT) to molecular methods to detect malaria in pregnancy. Using data from five completed studies, the association of epidemiological and pregnancy-related factors on the sensitivity of HS-RDT, and comparisons with co-RDT were investigated. The studies were conducted in 4 countries over a range of transmission intensities in largely asymptomatic women.
    Results: Sensitivity of both RDTs varied widely (HS-RDT range 19.6 to 85.7%, co-RDT range 22.8 to 82.8% compared to molecular testing) yet HS-RDT detected individuals with similar parasite densities across all the studies including different geographies and transmission areas [geometric mean parasitaemia around 100 parasites per µL (p/µL)]. HS-RDTs were capable of detecting low-density parasitaemias and in one study detected around 30% of infections with parasite densities of 0-2 p/µL compared to the co-RDT in the same study which detected around 15%.
    Conclusion: The HS-RDT has a slightly higher analytical sensitivity to detect malaria infections in pregnancy than co-RDT but this mostly translates to only fractional and not statistically significant improvement in clinical performance by gravidity, trimester, geography or transmission intensity. The analysis presented here highlights the need for larger and more studies to evaluate incremental improvements in RDTs. The HS-RDT could be used in any situation where co-RDT are currently used for P. falciparum diagnosis, if storage conditions can be adhered to.
    MeSH term(s) Adult ; Pregnancy ; Child ; Humans ; Female ; Plasmodium falciparum ; Rapid Diagnostic Tests ; Sensitivity and Specificity ; Malaria ; Malaria, Falciparum/diagnosis ; Malaria, Falciparum/epidemiology ; Diagnostic Tests, Routine/methods ; Antigens, Protozoan/analysis
    Chemical Substances Antigens, Protozoan
    Language English
    Publishing date 2023-02-20
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 2091229-8
    ISSN 1475-2875 ; 1475-2875
    ISSN (online) 1475-2875
    ISSN 1475-2875
    DOI 10.1186/s12936-023-04445-1
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Stillbirths: the hidden burden of malaria in pregnancy.

    Taylor, Steve M / Ter Kuile, Feiko O

    The Lancet. Global health

    2017  Volume 5, Issue 11, Page(s) e1052–e1053

    Language English
    Publishing date 2017-11
    Publishing country England
    Document type Journal Article
    ZDB-ID 2723488-5
    ISSN 2214-109X ; 2214-109X
    ISSN (online) 2214-109X
    ISSN 2214-109X
    DOI 10.1016/S2214-109X(17)30378-9
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Evaluation of community-based vector surveillance system for routine entomological monitoring under low malaria vector densities and high bed net coverage in western Kenya.

    Abong'o, Bernard / Stanton, Michelle C / Donnelly, Martin J / Ochomo, Eric / Ter Kuile, Feiko O / Samuels, Aaron M / Kariuki, Simon / Musula, George / Oxborough, Richard / Munga, Stephen / Torr, Steve J / Gimnig, John E

    Malaria journal

    2023  Volume 22, Issue 1, Page(s) 203

    Abstract: Background: Entomological surveillance is traditionally conducted by supervised teams of trained technicians. However, it is expensive and limiting in the number of sites visited. Surveillance through community-based collectors (CBC) may be more cost- ... ...

    Abstract Background: Entomological surveillance is traditionally conducted by supervised teams of trained technicians. However, it is expensive and limiting in the number of sites visited. Surveillance through community-based collectors (CBC) may be more cost-effective and sustainable for longitudinal entomological monitoring. This study evaluated the efficiency of CBCs in monitoring mosquito densities compared to quality-assured sampling conducted by experienced entomology technicians.
    Methods: Entomological surveillance employing CBCs was conducted in eighteen clusters of villages in western Kenya using indoor and outdoor CDC light traps and indoor Prokopack aspiration. Sixty houses in each cluster were enrolled and sampled once every month. Collected mosquitoes were initially identified to the genus level by CBCs, preserved in 70% ethanol and transferred to the laboratory every 2 weeks. Parallel, collections by experienced entomology field technicians were conducted monthly by indoor and outdoor CDC light traps and indoor Prokopack aspiration and served as a quality assurance of the CBCs.
    Results: Per collection, the CBCs collected 80% fewer Anopheles gambiae sensu lato (s.l.) [RR = 0.2; (95% CI 0.14-0.27)] and Anopheles coustani [RR = 0.2; (95% CI 0.06-0.53)] and 90% fewer Anopheles funestus [RR = 0.1; (95% CI 0.08-0.19)] by CDC light traps compared to the quality assured (QA) entomology teams. Significant positive correlations were however observed between the monthly collections by CBCs and QA teams for both An. gambiae and An. funestus. In paired identifications of pooled mosquitoes, the CBCs identified 4.3 times more Anopheles compared to experienced technicians. The cost per person-night was lower in the community-based sampling at $9.1 compared to $89.3 by QA per collection effort.
    Conclusion: Unsupervised community-based mosquito surveillance collected substantially fewer mosquitoes per trap-night compared to quality-assured collection by experienced field teams, while consistently overestimating the number of Anopheles mosquitoes during identification. However, the numbers collected were significantly correlated between the CBCs and the QA teams suggesting that trends observed by CBCs and QA teams were similar. Further studies are needed to evaluate whether adopting low-cost, devolved supervision with spot checks, coupled with remedial training of the CBCs, can improve community-based collections to be considered a cost-effective alternative to surveillance conducted by experienced entomological technicians.
    MeSH term(s) Animals ; Humans ; Malaria ; Anopheles ; Kenya/epidemiology ; Mosquito Vectors ; Feeding Behavior ; Mosquito Control
    Language English
    Publishing date 2023-07-03
    Publishing country England
    Document type Journal Article
    ZDB-ID 2091229-8
    ISSN 1475-2875 ; 1475-2875
    ISSN (online) 1475-2875
    ISSN 1475-2875
    DOI 10.1186/s12936-023-04629-9
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top